BACKGROUND: Severe burn injuries are known to initiate a profound systemic inflammatory response (SIRS) that may lead to burn shock and other SIRS-related complications. Damage-associated molecular patterns (DAMPs) are important early signaling molecules that initiate SIRS after burn injury. Previous work in a rodent model has shown that application of a topical immune modulator (p38MAPK inhibitor) applied directly to the burn wound decreases cytokine expression, reduces pulmonary inflammation and edema. Our group has demonstrated that tranexamic acid (TXA)-in addition to its use as an antifibrinolytic-has cell protective in vitro effects. We hypothesized that administration of TXA after burn injury would attenuate DAMP release and reduce lung inflammation. METHODS: C57/BL6 male mice underwent a 40% Total Body Surface Area (TBSA) scald burn. Sham animals underwent the same procedure in room temperature water. One treatment group received the topical application of p38MAPK inhibitor after burn injury. The other treatment group received an intraperitoneal administration of TXA after burn injury. Animals were sacrificed at 5 hours. Plasma was collected by cardiac puncture. MtDNA levels in plasma were determined by quantitative Polymerase Chain Reaction (qPCR). Syndecan-1 levels in plasma were measured by ELISA. Lungs were harvested, fixed, and paraffin-embedded. Sections of lungs were stained for antigen to detect macrophages. RESULTS: Topical p38MAPK inhibitor and TXA significantly attenuated mtDNA release. Both TXA and the topical p38MAPK inhibitor reduced lung inflammation as represented by decreased macrophage infiltration. Syndecan-1 levels showed no difference between burn and treatment groups. CONCLUSION: Both p38 MAPK inhibitor and TXA demonstrated the ability to attenuate burn-induced DAMP release and lung inflammation. Beyond its role as an antifibrinolytic, TXA may have significant anti-inflammatory effects pertinent to burn resuscitation. Further study is required; however, TXA may be a useful adjunct in burn resuscitation.
BACKGROUND: Severe burn injuries are known to initiate a profound systemic inflammatory response (SIRS) that may lead to burn shock and other SIRS-related complications. Damage-associated molecular patterns (DAMPs) are important early signaling molecules that initiate SIRS after burn injury. Previous work in a rodent model has shown that application of a topical immune modulator (p38MAPK inhibitor) applied directly to the burn wound decreases cytokine expression, reduces pulmonary inflammation and edema. Our group has demonstrated that tranexamic acid (TXA)-in addition to its use as an antifibrinolytic-has cell protective in vitro effects. We hypothesized that administration of TXA after burn injury would attenuate DAMP release and reduce lung inflammation. METHODS: C57/BL6 male mice underwent a 40% Total Body Surface Area (TBSA) scald burn. Sham animals underwent the same procedure in room temperature water. One treatment group received the topical application of p38MAPK inhibitor after burn injury. The other treatment group received an intraperitoneal administration of TXA after burn injury. Animals were sacrificed at 5 hours. Plasma was collected by cardiac puncture. MtDNA levels in plasma were determined by quantitative Polymerase Chain Reaction (qPCR). Syndecan-1 levels in plasma were measured by ELISA. Lungs were harvested, fixed, and paraffin-embedded. Sections of lungs were stained for antigen to detect macrophages. RESULTS: Topical p38MAPK inhibitor and TXA significantly attenuated mtDNA release. Both TXA and the topical p38MAPK inhibitor reduced lung inflammation as represented by decreased macrophage infiltration. Syndecan-1 levels showed no difference between burn and treatment groups. CONCLUSION: Both p38 MAPK inhibitor and TXA demonstrated the ability to attenuate burn-induced DAMP release and lung inflammation. Beyond its role as an antifibrinolytic, TXA may have significant anti-inflammatory effects pertinent to burn resuscitation. Further study is required; however, TXA may be a useful adjunct in burn resuscitation.
Authors: Steven E Wolf; David S Kauvar; Charles E Wade; Leopoldo C Cancio; Evan P Renz; Edward E Horvath; Christopher E White; Myung S Park; Sandra Wanek; Michael A Albrecht; Lorne H Blackbourne; David J Barillo; John B Holcomb Journal: Ann Surg Date: 2006-06 Impact factor: 12.969
Authors: John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle Journal: JAMA Date: 2015-02-03 Impact factor: 56.272
Authors: Xiao Yao; Jane G Wigginton; David L Maass; Lisha Ma; Deborah Carlson; Steven E Wolf; Joseph P Minei; Qun S Zang Journal: Am J Physiol Heart Circ Physiol Date: 2014-01-24 Impact factor: 4.733
Authors: Damien Carter; Adelaide Warsen; Katherine Mandell; Joseph Cuschieri; Ronald V Maier; Saman Arbabi Journal: J Burn Care Res Date: 2014 Mar-Apr Impact factor: 1.845
Authors: Jon D Simmons; Yann-Leei Lee; Sujata Mulekar; Jamie L Kuck; Sidney B Brevard; Richard P Gonzalez; Mark N Gillespie; William O Richards Journal: Ann Surg Date: 2013-10 Impact factor: 12.969
Authors: Elaheh Rahbar; Jessica C Cardenas; Gyulnar Baimukanova; Benjamin Usadi; Roberta Bruhn; Shibani Pati; Sisse R Ostrowski; Pär I Johansson; John B Holcomb; Charles E Wade Journal: J Transl Med Date: 2015-04-12 Impact factor: 5.531
Authors: Ze Yu Huang; Qiang Huang; Han Jiang Zeng; Jun Ma; Bin Shen; Zong Ke Zhou; Fu Xing Pei Journal: BMC Musculoskelet Disord Date: 2019-09-04 Impact factor: 2.362
Authors: Mark Broadwin; Patrick E Grant; Michael P Robich; Monica L Palmeri; Frances L Lucas; Joseph Rappold; Robert S Kramer Journal: JTCVS Open Date: 2020-05-22
Authors: Philip C Spinella; Kimberly A Thomas; Isaiah R Turnbull; Anja Fuchs; Kelly Bochicchio; Douglas Schuerer; Stacey Reese; Adrian A Coleoglou Centeno; Christopher B Horn; Jack Baty; Susan M Shea; M Adam Meledeo; Anthony E Pusateri; Jerrold H Levy; Andrew P Cap; Grant V Bochicchio Journal: Front Immunol Date: 2020-09-08 Impact factor: 7.561